Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage
Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage
In order to determine the effectiveness and safety of early vitamin K1 use in reducing the
 risk of bleeding and improving prognosis in patients with spontaneous intracerebral
 hemorrhage. Patients with spontaneous intracerebral hemorrhage (excluding rupture of aneurysm
 and vascular malformation) will be randomly divided into experimental group and control
 group. All the patients in the two groups were treated according to the guideline of
 spontaneous intracerebral hemorrhage. Patients in the experimental group was treated with
 intravenous injection of vitamin K1 20mg once a day for 2 days after admission, and the
 patients in control group was treated with normal saline as a control. The hematoma volume,
 coagulation function, platelet levels and GCS scales of the two groups will be recorded in
 0d, 1d, 3d, 7d post bleeding stroke, furthermore, length of ICU stay and total
 hospitalization, incidence of complications during hospitalization are to be recorded. During
 the follow-up, mRS score will be recorded at 1m and 6m post bleeding stroke.
Spontaneous intracerebral hemorrhage is a common disease in the department of neurosurgery,
 which often leads to long-term coma and severe neurological dysfunction. The amount of
 cerebral hemorrhage is directly related to the prognosis of the patients, and a small number
 of patients still suffer from the adverse consequences of delayed bleeding after active
 treatment. Vitamin K1 is a necessary ingredient in the liver to produce clotting factors II,
 VII, IX, and X, and vitamin K1 supplementation increases clotting function. On the contrary,
 vitamin K1 increases the risk of thrombosis. In this study, patients with spontaneous
 intracerebral hemorrhage (excluding rupture of aneurysm and vascular malformation) will be
 randomly divided into experimental group and control group. All the patients in the two
 groups were treated according to the guideline of spontaneous intracerebral hemorrhage.
 Patients in the experimental group was treated with intravenous injection of vitamin K1 20mg
 once a day for 2 days after admission, and the patients in control group was treated with
 normal saline as a control. The hematoma volume, coagulation function, platelet levels and
 GCS scales of the two groups will be recorded in 0d, 1d, 3d, 7d post bleeding stroke,
 furthermore, length of ICU stay and total hospitalization, incidence of complications during
 hospitalization are to be recorded. During the follow-up, mRS score will be recorded at 1m
 and 6m post bleeding stroke. Finally, the effectiveness and safety of early vitamin K1 use in
 reducing the risk of bleeding and improving prognosis in patients with spontaneous
 intracerebral hemorrhage will be analyzed.
Inclusion Criteria:

 -  Spontaneous intracerebral hemorrhage (Non - aneurysmal or arteriovenous malformations
 which confirmed by cerebral arterial CT enhancement or DSA);

 -  Age 18-65 years, male or non-pregnant female;

 -  GCS score at admission (4 to12);

 -  during the hospitalization, no urokinase and other hemostatic drugs were used except
 for etamsylate and vitamin K1;

 -  informed consent signed by the patient's family

 Exclusion Criteria:

 -  irregular lobulated hematoma (volume of hematoma can not be calculated accurately),
 such as intraventricular hemorrhage;

 -  severe liver disease or impaired liver function;

 -  pregnant or lactating women;

 -  history of using anticoagulation or antiplatelet aggregation drug (including
 Cilostazol, aspirin, dipyridamole, heparin, low molecular weight heparin, hirudin,
 dabigatran, and warfarin);

 -  non-accepted informed consent